Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
BIOJECT MEDICAL TECHNOLOGIES INC (BJCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/27/2015 |
8-K
| Quarterly results |
| 08/14/2015 |
8-K
| Quarterly results |
| 05/15/2015 |
8-K
| Quarterly results |
| 04/01/2015 |
8-K
| Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Departure of Directors or Certain ...|
Docs:
|
"Note from Company to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $116,636",
"Security Agreement dated March 3, 2015, by and among the Company, Bioject Inc. and Mark A. Logomasini & Associates, Inc. SEP Fund",
"Note from the Company to John E. Anderson in the principal sum of $50,000",
"Note from the Company to Sam Bhattacharjee in the principal sum of $50,000",
"Note from the Company to Sam Bhattacharjee in the principal sum of $50,000",
"Note from the Company to Life Sciences Opportunities Fund II, LP in the principal sum of $45,552",
"Note from the Company to Life Sciences Opportunities Fund (Institutional) II. LP in the principal sum of $254,448",
"Security Agreement dated February 18, 2015, by and among the Company, Bioject Inc., Life Sciences Opportunities Fund II, LP and Life Sciences Opportunities Fund (Institutional) II, LP",
"BIOJECT REPORTS UNAUDITED YEAR-END AND FOURTH QUARTER 2014 FINANCIAL RESULTS Tigard, OR - March 25, 2015 - Bioject Medical Technologies Inc. , a developer and manufacturer of needle-free injection therapy systems, today reported unaudited financial results for the year and quarter ended December 31, 2014. The financial results are unaudited and actual results may vary. 12 Months Ended December 31, 2014" |
|
| 02/13/2015 |
SC 13D/A
| LIFE SCIENCES OPPORTUNITIES FUND II LP reports a 67.6% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 11/12/2014 |
8-K
| Quarterly results |
| 08/15/2014 |
8-K
| Quarterly results|
Docs:
|
"Form of Note from Bioject to the Mark A. Logomasini & Associates, Inc. SEP Fund in the principal amount of $100,000",
"For value received,",
"SECURITY AGREEMENT This Security Agreement is made June 25, 2014 by and among Bioject Medical Technologies Inc. and its wholly owned subsidiary Bioject Inc. , each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 , and Mark A. Logomasini & Associates, Inc. SEP Fund and Amir Ness, the holders of the Company's Senior Secured Bridge Promissory Notes in the amounts of $100,000 and $50,000, respectively, dated June 23, 2014 and June 25, 2014, respectively and with the addresses set forth on the signature page hereto . RECITALS The Noteholders have agreed to make a secured loan to the Company, evidenced by the Notes, are secured by all the accounts receivable from Ferring Pharmaceuticals to the Company, whether presently existing or hereafter acquire...",
"BIOJECT REPORTS UNAUDITED SECOND QUARTER 2014 FINANCIAL RESULTS" |
|
| 07/31/2014 |
SC 13D
| FLYNN EDWARD L reports a 14.8% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 07/03/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/03/2014 |
SC 13D
| Logomasini Mark reports a 14.5% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 06/05/2014 |
4
| LIFE SCIENCES OPPORTUNITIES FUND II LP (10% Owner) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 06/03/2014 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/03/2014 |
4
| FARRELL CHRISTINE (Vice President of Finance) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 06/03/2014 |
4
| Tierney David S (Director) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 06/03/2014 |
4
| FLYNN EDWARD L (10% Owner) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC|
Txns:
| Converted 784,200 shares
@ $0.75, valued at
$588.2k
Converted 547,220 shares
@ $0.13, valued at
$71.1k
Converted 784,200 preferred shares
@ $0.75, valued at
$588.2k
Converted 547,220 preferred shares
@ $0.13, valued at
$71.1k
Bought 6,176,800 options to buy
@ $0.075, valued at
$463.3k
|
|
| 06/03/2014 |
4
| Logomasini Mark (President and CEO) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 06/03/2014 |
SC 13D/A
| LIFE SCIENCES OPPORTUNITIES FUND II LP reports a 50.6% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 05/15/2014 |
8-K
| Quarterly results |
| 05/06/2014 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/20/2014 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 10/01/2013 |
8-K
| Quarterly results |
| 08/30/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/17/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/20/2013 |
4
| Logomasini Mark (President & CEO) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 02/20/2013 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"LOGOMASINI EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement is dated February 15, 2013 between: BIOJECT MEDICAL TECHNOLOGIES INC. , a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 BIOJECT INC . , a corporation incorporated under the laws of the State of Oregon having its principal offices at 7180 SW Sandburg Street, Suite 100, Tigard, OR 97223 AND: Mark Logomasini, having an office address at 26212 Dimension Drive, Suite 260, Lake Forest, CA 92630 . RECITALS WHEREAS, the Executive has heretofore been employed by the Company. WHEREAS, the Company and Executive desire to set forth in this agreement the terms and conditions of Executive's employment with the Company. NOW, TH..." |
|
| 02/19/2013 |
4
| LIFE SCIENCES OPPORTUNITIES FUND II LP (10% Owner) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 02/19/2013 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities |
| 02/19/2013 |
4
| LIFE SCIENCES OPPORTUNITIES FUND II LP (10% Owner) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 02/15/2013 |
SC 13D/A
| LIFE SCIENCES OPPORTUNITIES FUND II LP reports a 59.5% stake in BIOJECT MEDICAL TECHNOLOGIES INC. |
| 02/06/2013 |
4
| LIFE SCIENCES OPPORTUNITIES FUND II LP (10% Owner) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 02/05/2013 |
4
| LIFE SCIENCES OPPORTUNITIES FUND II LP (10% Owner) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 01/28/2013 |
4
| Logomasini Mark (CEO/President) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
| 01/28/2013 |
4
| FLYNN EDWARD L (Director) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC|
Txns:
| Bought 26,316 options to buy
@ $0.19, valued at
$5k
Disposed/sold 52,632 options to buy
@ $0.19, valued at
$10k
Bought 3,794,857 options to buy
@ $0.035, valued at
$132.8k
|
|
| 01/28/2013 |
4
| Hansen Albert (Director) has filed a Form 4 on BIOJECT MEDICAL TECHNOLOGIES INC |
|
|
|